Cipla Signals Lanreotide Supply Strain, Eyes First Wave GLP-1 India Entry
Cipla Scion To Shepherd ‘Value Systems, Growth Agenda’
Lanreotide supply challenges could impact Cipla’s US revenues in the coming quarter, while the firm hopes it can seize emerging opportunities in the GLP-I segment in India, where Novo Nordisk and Eli Lilly are progressing filings for their blockbuster products.
